Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
GNFT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.55 - $6.42
Previous CloseN/A
Volume1.39K
Average Volume (3M)5.01K
Market Cap
$184.75M
Enterprise Value$222.30M
Total Cash (Recent Filing)$81.79M
Total Debt (Recent Filing)$62.13M
Price to Earnings (P/E)109.7
Beta0.68
Next Earnings
Apr 09, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding50,002,890
10 Day Avg. Volume9,578
30 Day Avg. Volume5,011
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda28.52
Forecast
1Y Price Target
$7.50Price Target Upside97.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityGenfit remains well capitalized, with a cash runway beyond 2028, providing financial stability and potential for future growth.
Market LeadershipDespite the VS-01 discontinuation, Genfit remains the clear industry leader in ACLF, showcasing its strong position in the market.
Revenue GenerationThe diagnostic NIS2+ platform for NASH risk stratification, partnered with Labcorp, is generating revenue and provides non-dilutive upside tied to the success of emerging NASH therapies.
Bears Say
Pipeline DiscontinuationThe discontinuation of VS-01 in ACLF is a near term headwind due to the fragile ICU patient population and elevated infection risk.
Stock ValuationAt current levels, GNFT stock reflects minimal value for its ACLF pipeline, which does not reflect a fair probability of success in ACLF, and underestimates the market potential of a successful ACLF therapy.
Genfit SA News
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $2.55 and its highest was $6.42 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $184.75M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 09, 2026 which is in 189 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 22, 2025. The company reported -$0.236 earnings per share for the quarter, missing the consensus estimate of $1.192 by -$1.428.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.28.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,002,890 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$0.236 in its last earnings report, missing expectations of $1.192. Following the earnings report the stock price went down -12.53%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFT
Genfit SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (97.37% Upside)
$7.50 (97.37% Upside)
Blogger Sentiment
Bullish
GNFT Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.96%
12-Months-Change
Fundamentals
Return on Equity
-51.06%
Trailing 12-Months
Asset Growth
22.06%
Trailing 12-Months
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFT Stock 12 Month Forecast
Average Price Target
$7.50
▲(97.37% Upside)
Technical Analysis
Omeros
―
Y-Mabs Therapeutics
―
RAPT Therapeutics
―
4D Molecular Therapeutics
―
enGene Holdings
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---